XML 50 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Total revenues $ 21,323 $ 38,406 $ 34,305 $ 73,746
Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 3,937 3,614 6,521 7,347
EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 8,349 4,690 11,438 8,817
APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 9,037 30,102 16,346 57,582
Product revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 11,048 34,645 19,412 65,335
Research and development revenue        
Disaggregation of Revenue [Line Items]        
Total revenues 10,275 3,761 14,893 8,411
Performance Enzymes        
Disaggregation of Revenue [Line Items]        
Total revenues 19,308 36,530 28,794 69,629
Performance Enzymes | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 3,671 2,307 4,589 4,861
Performance Enzymes | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 6,600 4,121 7,859 7,186
Performance Enzymes | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues 9,037 30,102 16,346 57,582
Novel Biotherapeutics        
Disaggregation of Revenue [Line Items]        
Total revenues 2,015 1,876 5,511 4,117
Novel Biotherapeutics | Americas        
Disaggregation of Revenue [Line Items]        
Total revenues 266 1,307 1,932 2,486
Novel Biotherapeutics | EMEA        
Disaggregation of Revenue [Line Items]        
Total revenues 1,749 569 3,579 1,631
Novel Biotherapeutics | APAC        
Disaggregation of Revenue [Line Items]        
Total revenues $ 0 $ 0 $ 0 $ 0